Moberg Derma and PharmaPlan Sign Agreement for NALOX/EMTRIX in South Africa

Published: Mar 27, 2012

STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:

Moberg Derma AB (STO:MOB) has entered into a distribution agreement with Pharmaplan (Pty) Ltd. for Nalox™//Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Pharmaplan is granted exclusive rights to market and sell Nalox™ /Emtrix® in South Africa. Moberg Derma assumes production and supply responsibility.

Back to news